ScholarWorks@Korea University College of Medicine: Choi, Yoon Ji

Detailed Information

Choi, Yoon Ji (최윤지)

Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:5||Breast cancer:4||Breast neoplasms:4||Chemotherapy:3||Highthroughput nucleotide sequencing:3||overall survival:2||PDL1:2||prognosis:2||trastuzumabpkrb:2||urothelial carcinoma:2||prognostic model:2||Genomics:2||Febrile neutropenia:2||Colorectal neoplasms:2||HER2:2||Neoplasms:2||cellfree DNA:2||Korea National Health and Nutrition Examination Survey:2||Cardiac Tamponade:1||Castrationresistant prostate cancer:1||Castrationresistant prostatic neoplasm:1||Cellfree nucleic acids quantification:1||Cessation:1||Cisplatin:1||Cisplatinunfit:1||Clostridium difficile:1||Comorbidity:1||Congestive heart failure:1||Continuity of patient care:1||Doubleballoon enteroscopy:1||Dovitinib:1||Ecigarettes:1||Endoflife care:1||Enfortumab vedotin:1||Epidermal growth factor receptor mutation:1||Eribulin:1||FOLFIRI:1||FOLFOX:1||Gefitinib:1||Gemcitabine:1||Genomic landscape:1||Germline mutation:1||Goserelin:1||Hereditary nonpolyposis colon cancer:1||Hyponatremia:1||IFNγ:1||Inflammation:1||Intercalated chemotherapy:1||Jejunal neoplasm:1||KRAS:1||Khorana score:1||Korean:1||Liver:1||Lung adenocarcinoma:1||Lymph node excision:1||Lymph nodes:1||Lymphoma:1||Malignancy:1||Metabolic tumor volume:1||Metastasis:1||Metastatic burden:1||Metastatic cancer:1||Molecular:1||Mutation:1||Neoadjuvant therapy:1||Neoplasm:1||Neoplasm metastasis:1||Neuroendocrine carcinoma (NEC):1||Neuroendocrine tumor (NET):1||Neutropenia:1||Nonsmall cell lung cancer:1||Nonsmallcell lung cancer:1||Nonsmallcell lung carcinoma:1||Octreotide:1||Oral health:1||Ovarian function suppression:1||Ovarian neoplasms:1||Overall survival:1||Oxaliplatin:1||PDL2:1||PIK3CA mutation:1||Pancreatic adenocarcinoma:1||Pancreatic cancer:1||Pancreatic neoplasms:1||Pathology:1||Pemetrexed:1||Phase IV clinical trial:1||Physician orders for lifesustaining treatment:1||Pneumonitis:1||Postprogression survival:1||Practice guideline:1||Precision medicine:1||Predictive value:1||Prednisolone:1||Premenopause:1||Primary Pericardial Mesothelioma:1||Principal component analysis:1||Prognostic biomarker:1||Prognostic factors:1||Prostate neoplasms:1||Risk:1||Safety:1||Secondline chemotherapy:1||Serum:1||Small cell lung cancer:1||Smoker:1||Smoking:1||Stage:1||Survival:1||TGFβ1:1||TNFα:1||Tamoxifen:1||Targetable gene alteration:1||Tooth loss:1||Total lesion glycolysis:1||Toxocariasis:1||Trastuzumab:1||Treatment outcome:1||Tumor mutation burden:1||Tyrosine kinase inhibitors:1||Urinary bladder:1||Urothelial cancer:1||Urothelial carcinoma:1||Venous thromboembolism:1||Visceral larva migrans:1||WildType EGFR:1||aggressive fibromatosis:1||bladder cancer:1||brain metastasis:1||cancer:1||cancer patients:1||cancer survivors:1||capecitabine:1||cardiovascular disease:1||cellfree DNA concentration:1||chemotherapy:1||cholangiocarcinoma:1||cisplatin:1||colorectal cancer:1||coronavirus disease 2019:1||direct oral anticoagulants:1||docetaxelPM:1||hand strength:1||head and neck cancer:1||head and neck cancers:1||leucovorin:1||lowmolecularweight heparin:1||lung cancer:1||lung function:1||malignant salivary gland tumors:1||mammalian target of rapamycin inhibitor (mTOR inhibitor):1||methotrexate:1||missense mutation:1||mitomycin:1||molecular targeted therapy:1||multiplex polymerase chain reaction:1||mutations:1||neoplasms:1||nonsmall cell lung cancer:1||nonsmallcell lung cancer:1||nonsmallcell lung carcinoma:1||obstructive lung disease:1||paclitaxel:1||pemetrexed:1||perception:1||prognostic indicator:1||prognostic value:1||quality of life:1||refractory colon cancer:1||relapsefree survival:1||risk:1||safety:1||salivary duct carcinoma:1||screening:1||secondline chemotherapy:1||sequencing:1||sirolimus:1||stroke:1||survivorship:1||targeted therapy:1||tumorinfiltrating lymphocytes:1||vaccine:1||venous thromboembolism:1||& nbsp:1||vinblastine:1||5FU:1||Adjuvant chemotherapy:1||Adjuvant endocrine therapy:1||Advance directives:1||Advanced lung cancer:1||Anthracycline:1||BRCA:1||BRCA1 gene:1||Biliary tract cancer:1||Biomarkers:1||Bone morphogenetic protein2:1||COVID19:1||CTLA4:1||CXCR4:1||Cabazitaxel:1||Cancer survivors:1||Carboplatin:1||

STATISTICS: Total View :12,632,538; Today View :10,138

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE